NUTRIARX CREAMPAK- triamcinolone acetonide, dimethicone NuCare Pharmaceuticals,Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Dimethicone, 118mL (68599-0213-4)

Drug Facts

Active ingredient

Dimethicone 5.0%

Purpose

Skin Protectant

Uses

For the treatment and / or prevention of diaper rash temporarily protects and helps relieve chapped or cracked skin

Warnings

For external use only.

- When using this product
- do not get into eyes

Do not use on

- deep or puncture wounds
- animal bites
- serious burns

Stop use and ask a doctor if

- condition worsens
- symptoms last more than 7 days or clear up and occur again within a few days

keep out of reach of children

If swallowed, get medical help or contact a Poison Control Center right away.

Directions

- Cleanse skin with Thera Moisturizing Body Cleanser or Thera Foaming Body Cleanser
- Apply cream liberally until entire area is covered
- Apply as needed

Other information

Store at 40-95°F (4-35°C)

Inactive Ingredients

Inactive Ingredients:

Purified Water, Glyceryl Stearate, PEG 100 Stearate, Stearic Acid, Aleurites Moluccana Seed Oil. Cetyl Alcohol, Glycerin, Butylene Glycol, Carthamus Tinctorius (Safflower) Seed Oil, Dimethicone Crosspolymer, Calcium Pantothenate (Vitamin B5), Maltodextrin, Niacinamide (Vitamin B3), Pyridoxine HCL (Vitamin B6), Silica, Sodium Ascorbyl Phosphate (Vitamin C), Sodium Starch Octenylsuccinate, Tocopheryl Acetate (Vitamin E), Disodium EDTA, Sodium Hyaluronate, Aloe Barbadensis Leaf Extract. Zingiber Officinale (Ginger) Root Extract, Carthamus Tinctorius (Safflower) Oleosomes, Fragrance, Phenoxyethanol, Caprylyl Glycol, Chlorphenesin, Bisabolol, Lysine, Histidine, Arginine, Aspartic Acid, Threonine, Serine, Glutamic Acid, Proline, Glycine, Alanine, Valine, Methionine, Isoleucine, Leucine. Tyrosine, Phenylalanine, Cysteine, Triethanolamine

QUESTIONS

Questions ?

Call 1-800-777-4908

Trimcinolone Acetonide Cream USP , 80mg(45802-064-36)


For Dermatologic Use Only

Not For Ophthalmic Use

Rx Only

DESCRIPTION

The topical corticosteroids constitute a class of primarily synthetic steroids used as antiinflammatory and anti-pruritic agents. Triamcinolone acetonide is designated chemically as pregna-1,4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene) bis (oxy)]-,(11ß,16 α)-. C 24H 31FO 6, and M.W. of 434.51; CAS Reg. No. 76-25-5.



Each gram of 0.025%, 0.1% and 0.5% Triamcinolone Acetonide Cream USP contains 0.25 mg, 1 mg, or 5 mg triamcinolone acetonide respectively, in a washable cream base of cetyl alcohol, cetyl esters wax, glycerin, glyceryl monostearate, isopropyl palmitate, polysorbate-60, propylene glycol, purified water, sorbic acid, and sorbitan monostearate.

CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

PHARMACOKINETICS

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see **DOSAGE AND ADMINISTRATION**). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS & USAGE

Triamcinolone acetonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRADICTIONS

Triamcinolone acetonide cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

GENERAL

Systemic absorption of topical corticosteroids has produced reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see **PRECAUTIONS-Pediatric Use**).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

INFORMATION FOR PATIENTS

Patients using topical corticosteroids should receive the following information and instructions.

- 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
- 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
- 4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
- 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

LABORATORY TESTS

The following tests may be helpful in evaluating the HPA axis suppression:

Urinary free cortisol test

ACTH stimulation test

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

PREGNANCY CATEGORY C

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are not adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

NURSING MOTHERS

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

PEDIATRIC USE

Pediatric patients may demonstrate greater susceptibility to topical corticosteroidinduced HPA axis suppressionand Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic- pituitary-adrenal (HPA) axis suppression, Cushings's syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

DOSAGE & ADMINISTRATION

Topical corticosteroids are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.

Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressing should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

Triamcinolone acetonide cream USP 0.1% is supplied in 80 g tube NDC 45802-064-36

Store at 20-25°C (68°-77°F) [see USP Controlled Room Temperature].

Avoid excessive heat. Protect from freezing.

PRINTED IN USA

Manufactured for: Ascend Laboratories, LLC Montvale, NJ 07645

Manufactured by: Crown Laboratories, Inc. Johnson City, TN 37604

P1810.01

Revised: Sept 2015

SILICONE TAPE

Silicone Tape

Uses

• To be applied to wounds or scars as a protective silicone barrier.

• As a dressing for abrasions, surgical wounds, donor sites, lacerations, ulcers, skin tears, superficial partial thickness burns, venous leg ulcers.

• As a dressing/securement for IV related uses, pressure ulcers, skin care, and wound care


Precautions

- Do not use if you are allergic to silicone
- Keep out of reach of children

Directions for use

• Apply tape to wound or scar as needed or as directed by your physician. Remove tape, wash area, and apply new tape at least every 24 hours.


DIMETHICONE



TRIMCINOLONE ACETONIDE CREAM USP



NuTriaRX CreamPAK



NUTRIARX CR							
triamcinolone acetor	nide, dime	ethicone kit					
Product Informa	tion						
Product Type	HUMAN PRE	ESCRIPTION DRUG	Item Code (Source)	NDC:70859-054			
Packaging							
# Item Code	Packa	ge Description	Marketing Start Date	Marketing End Date			
1 NDC:70859-054-01	1 in 1 KIT		06/03/2020				
Quantity of Parts	5						
-							
Part 1 1 BOTTLE	-		118 mL				
Part 2 1 TUBE			80 g				
Part 1 of 2							
DIMETHICONE	1						
body shield cream							
Product Informa	tion						
Item Code (Source)		NDC:68599-0213					
Route of Administra	ation	TOPICAL					
Active Ingredient	ACTIVE	моюту					

Ingredient Name	Basis of Strength	Strength
DIMETHICONE (UNII: 92RU3N3Y10) (DIMETHICONE - UNII:92RU3N3Y10)	DIMETHICONE	50 mg in 1 mL
		3
Inactive Ingredients		
Ingredient Name		Strength
CETYL ALCOHOL (UNII: 936JST6JCN)		
MALTODEXTRIN (UNII: 7CVR7L4A2D)		
LYSINE (UNII: K3Z4F929H6)		
SODIUM ASCORBYL PHOSPHATE (UNII: 836SJG51DR)		
EDETATE DISODIUM ANHYDROUS (UNII: 8NLQ36F6MM)		
TYROSINE (UNII: 42HK56048U)		
ARGININE (UNII: 94ZLA3W45F)		
KUKUI NUT OIL (UNII: TP11QR7B8R)		
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)		
TROLAMINE (UNII: 903K93S3TK)		
PYRIDOXINE HYDROCHLORIDE (UNII: 68Y4CF58BV)		
PHENOXYETHANOL (UNII: HIE492ZZ3T)		
PEG-100 STEARATE (UNII: YD01N1999R)		
STEARIC ACID (UNII: 4ELV7Z65AP)		
NIACINAMIDE (UNII: 25X51I8RD4)		
CHLORPHENESIN (UNII: 1670DAL4SZ)		
OCTENYLSUCCINIC ACID (UNII: 12UZ E4X73L)		
ALOE VERA LEAF (UNII: ZY81Z83H0X)		
LEVOMENOL (UNII: 24WE03BX2T)		
THREONINE (UNII: 2ZD004190S)		
CAPRYLYL GLYCOL (UNII: 00YIU5438U)		
ALANINE (UNII: OF5P57N2ZX)		
GLYCERYL MONOSTEARATE (UNII: 2300U9XXE4)		
SAFFLOWER OIL (UNII: 65UEH262IS)		
DIMETHICONE CROSSPOLYMER (450000 MPA.S AT 12% IN CYCLOPE UF7620L1W6)	NTASILOXANE) (UNII:	
CALCIUM PANTOTHENATE (UNII: 568ET80C3D)		
GLYCERIN (UNII: PDC6A3C0OX)		
HYALURONATE SODIUM (UNII: YSE9PPT4TH)		
GLUTAMIC ACID (UNII: 3KX376GY7L)		
ISOLEUCINE (UNII: 04Y7590D77)		
BUTYLENE GLYCOL (UNII: 3XUS85K0RA)		
VALINE (UNII: HG18B9YRS7)		
PHENYLALANINE (UNII: 47E5O17Y3R)		
METHIONINE (UNII: AE28F7PNPL)		
SERINE (UNII: 452VLY9402)		
GLYCINE (UNII: TE7660XO1C)		
ASPARTIC ACID (UNII: 30KYC7MIAI)		
WATER (UNII: 059QF0KO0R)		
GINGER (UNII: C5529G5JPQ)		
.ALPHATOCOPHEROL ACETATE (UNII: 9E8X80D2L0)		
HISTIDINE (UNII: 4QD397987E)		
CARTHAMUS TINCTORIUS (SAFFLOWER) OLEOSOMES (UNII: 95600723	309)	
PROLINE (UNII: 9DLQ4CIU6V)		

# tem Code Package Description Marketing Start Date Marketing En Date NDC:6899- 0213:4 118 mL in 1 BOTTLE; Type 0: Not a Combination Image: Composition of the second of the seco	# tem Code Package Description Marketing Start Date Marketing E Date MDC:6859- 0213:4 118 mL in 1 BOTTLE; Type 0: Not a Combination Image: Composition of the second secon	CYSTEINE (UNII: K84						
# tem Code Package Description Marketing Start Date Marketing En Date NDC:68599. 0213:4 118 mL in 1 BOTTLE; Type 0: Not a Combination Marketing Start Date Marketing En Date Marketing Information Marketing Start Citation Marketing Start Date Marketing En Date Marketing Information Application Number or Monograph Citation Marketing Start Date Marketing En Date DTC monograph final category Application Number or Monograph Citation Marketing Start Date Marketing En Date Part 2 of 2 TRIAMCINOLONE ACETONIDE triamcinolone acetonide cream NDC:45802-064 Strength Route of Administration TOPICAL TOPICAL TOPICAL Ingredient Strength Ingredient/Active Moiety UNII:F446C597KA) Ingredient Name Basis of Strength 1 mg ACETONIDE 1 mg ACETONIDE <th># tem Code Package Description Marketing Start Date Marketing E Date NDC:68599 (213:49 118 mL in 1 BOTTLE; Type 0: Not a Combination Product Image: Comparison of the Compariso</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	# tem Code Package Description Marketing Start Date Marketing E Date NDC:68599 (213:49 118 mL in 1 BOTTLE; Type 0: Not a Combination Product Image: Comparison of the Compariso							
NDC:68599- 1 118 mL in 1 BOTTLE; Type 0: Not a Combination Product Date Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Information Part 2 of 2 TRIAMCINOLONE ACETONIDE triamcinolone acetonide cream 08/12/2019 Vertication Product Information tume Code (Source) NDC:45802-064 Vertication Vertication Route of Administration TOPICAL TRIAMCINOLONE ACETONIDE triamcinolone acetonide cream TOPICAL Ingredient Name Active Ingredient/Active Molety Ingredient Name Basis of Strength AcETONIDE Ing Inactive Ingredients Ingredient Name Strength ACETONIDE Ing Inactive Ingredients Ingredient Name Strength ACETONIDE Ing Inactive Ingredients Ingredient Name Strength ACETONIDE Ing Inactive Ingredients Strength Ing Ing SorBitTAN MONOSTEARATE (UNII: KV240H58X) SORBITAN MONOSTEARATE (UNII: KV240H58X) SORBIC (LD (UNII: A0459098B) GUZERN (UNII: CO590F0K0R) Ing Marketing City (UNII: R0590F0K0R) GUZERN (UNII: R0590F0K0R) GUZERN (UNII: R0590F0K0R) Ing	NDC:68599- In 0213-4 IB mL in 1 B OTTLE; Type 0: Not a Combination Product Date Date Marketing Information Marketing Category Category Application Number or Monograph Citation Marketing Start Date Marketing E Date Part 2 of 2 TRIAMCINOLONE ACETONIDE triamcinolone acetonide cream 08/12/2019 V Product Information Item Code (Source) NDC:45802-064 NDC:45802-064 Strength Strength Route of Administration TOPICAL VDC:45802-064 Strength Strength Inactive Ingredient/Active Molety UNII:F446C597KA) Ingredient Name Basis of Strength Strength Inactive Ingredients Ingredient Name Basis of Strength Strength Inactive Ingredients Ingredient Name Strength Ingregient Strength PolysonBarte 60 (UNII: 2020/FM) Ingregient Name Strength Strength SorBic ActD (UNII: 936)STRON Ingregient Name Strength Ingregient Name Fory ActOHOL (UNII: 936)STRON Ingregient Name Strength Ingregient Name SorBic ActD (UNII: 936)STRON Ingregient Name Strength Ingregient Name SorBic ActD (UNII:	Packaging						
O213-4 Product Product Marketing Information Marketing Start Application Number or Monograph Date Marketing Category Application Number or Monograph Date OTC monograph final part 3 O8/12/2019 Part 2 of 2 Product TRIAMCINOLONE ACETONIDE Value triamcinolone acetonide cream Porduct Product Information NDC:45802-064 Route of Administration TOPICAL Active Ingredient/Active Moiety Basis of Strength Strength Strength In g cetionide Ingredient Name Basis of Strength Strength Scrength CetyL ALCOHOL (UNII: 936)ST6)CN PolySorBarte 60 (UNII: CAL22UNAM) SorBit A MONOSTEARATE (UNII: NVZ4I0H58X) SorBit C ALDI (UNII: 2032)EFPGGU) GatyCetin (UNII: 9D26AGCOX) PopoyLene GuyCol (UNII: 6DC290167V3) Water (UNII: 0590F0KOOR)	O213-4 Product Marketing Information Marketing Edgory Application Number or Monograph Citation Marketing Edgory Marketing Edgory OTC monograph final part347 08/12/2019 Date Date Part 2 of 2 TRIAMCINOLONE ACETONIDE Edgory Edgory Edgory Product Information Item Code (Source) NDC:45802-064 Edgory Edgory Edgory Active Ingredient/Active Molety Ingredient Name Basis of Strength Strength Rume(INOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) Ingredient Strength Inactive Ingredients Ingredient Name Strength Strength CETYL ALCOHOL (UNII: 936)ST6/CN) Ingredient Name Strength Ingredient Strength SorBitA MONOSTEARATE (UNII: N22410H58X) SorBitA MONOSTEARATE (UNII: N22410H58X) SorBitA MONOSTEARATE (UNII: N22410H58X) SorBitA MONOSTEARATE (UNII: N22410H58X) Ingredient Name Strength CetYL ESTERS WAX (UNII: D072FFPGU) Ingredient Name Strength Ingredient Name Strength SorBitA MONOSTEARATE (UNII: N22410H58X) Ingredient Name Strength Ingredient Name	# Item Code	Pa	ckage Description		-		End
Category Citation Date Date OTC monograph final part347 08/12/2019 Image: Comparison of the comparison	Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing E DateOTC monograph final part347part34708/12/201908/12/2019Part 2 of 2TRIAMCINOLONE ACETONIDE triamcinolone acetonide creamProduct Information Item Code (Source)NDC:45802-064Route of AdministrationTOPICALActive Ingredient/Active Molety Ingredient NameBasis of Strength ACETONIDETRIAMCINOLONE ACETONIDE Ingredient NameStreet Basis of StrengthIngredient NameBasis of Strength ACETONIDEIngredient Ingredient NameIngredient NameStreet Basis of StrengthIngredient NameStrength CETVI ALCOHOL (UNII: 936)ST6JCN) POLYSORBATE 60 (UNII: CAL22UVI4M)Ingredient NameSorBit A MONOSTEARATE (UNII: NV24I0H58X) SORBITA MONOSTEARATE (UNII: NV24I0H58X) SORBITA MONOSTEARATE (UNII: NV24I0H58X)ImgredientGETYL ESTERS WAX (UNII: D072FFP9GU) GIYCERIN (UNII: 6045098989)ImgredientCETYL ESTERS WAX (UNII: D072FFP9GU) GIYCERIN (UNII: 604509167V3) WATER (UNII: 60509167V3) WATER (UNII: 60509167V3)Imgredient			OTTLE; Type 0: Not a Combination				
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Ent Date OTC monograph final part 2 of 2 o8/12/2019 Image: Comparison of Compar	Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing E DateOTC monograph final part347part34708/12/201908/12/2019Part 2 of 2TRIAMCINOLONE ACETONIDE triamcinolone acetonide creamProduct Information Item Code (Source)NDC:45802-064Route of AdministrationTOPICALActive Ingredient/Active Molety Ingredient NameBasis of Strength ACETONIDETRIAMCINOLONE ACETONIDE Ingredient NameStreet Basis of StrengthIngredient NameBasis of Strength ACETONIDEIngredient Ingredient NameIngredient NameStreet Basis of StrengthIngredient NameStrength CETVI ALCOHOL (UNII: 936)ST6JCN) POLYSORBATE 60 (UNII: CAL22UVI4M)Ingredient NameSorBit A MONOSTEARATE (UNII: NV24I0H58X) SORBITA MONOSTEARATE (UNII: NV24I0H58X) SORBITA MONOSTEARATE (UNII: NV24I0H58X)ImgredientGETYL ESTERS WAX (UNII: D072FFP9GU) GIYCERIN (UNII: 6045098989)ImgredientCETYL ESTERS WAX (UNII: D072FFP9GU) GIYCERIN (UNII: 604509167V3) WATER (UNII: 60509167V3) WATER (UNII: 60509167V3)Imgredient							
Category Citation Date Date OTC monograph final part347 08/12/2019 Image: Comparison of the comparison	Category Citation Date Date Date OTC monograph final part347 08/12/2019 08/12/2019 Part 2 of 2 TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE triamcinolone acetonide cream Product Information Item Code (Source) NDC: 45802-064 Route of Administration TOPICAL Active Ingredient/Active Molety Basis of Strength Street Ingredient Name TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRAMCINOLONE NE Ingredient Name Basis of Strength Ingredient Name Strength Ingredient Name Strength Ingredient Name Strength Strength Ingredient Name Strength Strength Ingredient Name Strength Strength Ingredient Name Strength <td>Marketing I</td> <td>nformat</td> <td>ion</td> <td></td> <td></td> <td></td> <td></td>	Marketing I	nformat	ion				
Part 2 of 2 TRIAMCINOLONE ACETONIDE triamcinolone acetonide cream Product Information Item Code (Source) NDC:45802-064 Route of Administration TOPICAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Ingredient Name Ing	Part 2 of 2 TRIAMCINOLONE ACETONIDE triamcinolone acetonide cream Product Information Item Code (Source) NDC:45802-064 Route of Administration TOPICAL Active Ingredient/Active Moiety TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE Ingredient Name Streength Ingredient Name Streength TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE Ingredients 1 mg Ingredient Name Streength CETYL ALCOHOL (UNII: 936]ST6JCN) Ingredient Name Streength SorBit A MONOSTERAATE (UNII: N2410H58X) Ingredient Name Streength SorBit CALD (UNII: X045WJ989B) Ingredient Name Ingredient Name SorBit CALD (UNII: X045WJ989B) Ingredient Name Ingredient		Applica					End
TRIAMCINOLONE ACETONIDE triamcinolone acetonide cream Product Information Item Code (Source) NDC:45802-064 Route of Administration TOPICAL Active Ingredient/Active Moiety Basis of Strength Strengt Ingredient Name TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE Ingredient Name Basis of Strength Strengt 1 mg ACETONIDE Ingredient Name Strength Ingredient Name Strength Ingredients 1 ng ACETONIDE Ingredient Name Strength Strength Strength Ingredient Name Strength Ingredient Name Strength Strength S	TRIAMCINOLONE ACETONIDE triamcinolone acetonide cream Product Information Item Code (Source) NDC:45802-064 Route of Administration TOPICAL Active Ingredient/Active Molety Ingredient Name Basis of Strength Strength TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRAMCINOLONE ACETONIDE UNII: F446C597KA) Ingredient Name Strength ACETONIDE UNII: F446C597KA) Ingredient Name Strength Strength CETYL ALCOHOL (UNII: 936JST6JCN) Ingredient Name POLYSORBATE 60 (UNII: CAL22UVIAM) SORBITAN MONOSTEARATE (UNII: NVZ 410H58X) SORBIC ACID (UNII: X045W9898) Ingredient S CETYL ESTERS WAX (UNII: b072FFPGU) Ingredient S SORBIC ACID (UNII: X045W9898) Ingredient S SORBIC ACID (UNII: S0200X) PROPYLENE GLYCOL (UNII: 60502167V3) WATER (UNII: 05904000R) Ingredient S ISOPROPYL PALMITATE (UNII: 8CR02TH63M) Ingredient S	OTC monograph fina	l part347		08/12/2019)		
Item Code (Source) NDC:45802-064 Route of Administration TOPICAL Active Ingredient/Active Moiety Basis of Strength Strength Ingredient Name Basis of Strength Strength Ingredient Name Basis of Strength Ingredient/Active Ingredient Name TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE ACETONIDE TRIAMCINOLONE ACETONIDE 1 mg in 1 g Ingredient Name Strength Strength Strength Ingredient Name Strength Strength CETYL ALCOHOL (UNII: 936JST6JCN) Ingredient Name Strength SoroBITAN MONOSTEARATE (UNII: NVZ 410H58X) Strength Strength Strength Strength Monostearate (UNII: NVZ 410H58X) Ingredient Strength Ingredient Strength CETYL ESTERS WAX (UNII: D072FFP9GU) Ingredient Strength Ingredient Strength Strength Strength Monostearate (UNII: NVZ 410H58X) Ingredient Strength Ingredient Strength Strength Strength Monostearate (UNII: D072FFP9GU) Ingredient Strength Ingredient Strength Strength Strength Monostearate (UNII: Strength Strengt	Item Code (Source) NDC:45802-064 Route of Administration TOPICAL Active Ingredient/Active Molecty Ingredient Name Basis of Strength Strength Ingredient Name Basis of Strength Img Ingredient Name Acetronide 1 mg Ingredient Name Strength Strength Ingredient Name Strength 1 mg Ingredient Name Strength 1 mg Ingredient Name Strength Strength Ingredient Name Strength 1 mg Ingredient Name Strength 1 mg SoroBitAn Monostearate (UNII: 0422UVI4M) Img Img SoroBitAn Monostearate (UNII: NVZ 410H58X) Img Img SoroBitA Cid (UNII: 2045W9898) Img Img CetYL Esters Wax (UNIII: D072FFP9GU) Img Img SoroBitA Cid (UNIII: 2045W9898) Img Img CetYL Esters Wax (UNII: D072FFP9GU) Img Img SoroBitA Cid (UNIII: 2045W9898) Img Img SoroBitA Cid (UNIII: 6059Q167V3) Img Img WAT							
Item Code (Source) NDC:45802-064 Route of Administration TOPICAL Active Ingredient/Active Moiety Active Ingredient/Active Moiety TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONICE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONICE	Item Code (Source) NDC:45802-064 Route of Administration TOPICAL Active Ingredient/Active Moiety Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Ingredient Name CETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE ACETONIDE TRIAMCINOLONE ACETONIDE UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE ACETONIDE UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE ACETONIDE IN In Igentiate Acetonic Aceto							
Ingredient/Active Moiety Basis of Strength Strength Route of Administration Ingredient Name Basis of Strength Imgredient Rective Ingredient/Active Moiety TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE Ingredients 1 mg Inactive Ingredients TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE Ingredients 1 mg Inactive Ingredients Strength Strength CETYL ALCOHOL (UNII: 936)ST6JCN) SorbitAn MONOSTEARATE (UNII: NVZ410H58X) SorbitAn MONOSTEARATE (UNII: NVZ410H58X) SorbitAn MONOSTEARATE (UNII: NVZ410H58X) SorbitA CID (UNII: 2045W989B) Image: SorbitA CID (UNII: 2045W989B) CETYL ESTERS WAX (UNII: D072FFP9GU) Image: SorbitA CID (UNII: 2045W07400 SorbitA CID (UNII: 2045W0740 Sorbit	Instruction TOPICAL Active Ingredient/Active Moiety Basis of Strength Strength Ingredient Name Basis of Strength Strength TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 1 mg Inactive Ingredients Ingredient Name Strength Strength Inactive Ingredients Strength Strength Strength Inactive Ingredients Ingredient Name Strength CETYL ALCOHOL (UNII: 936)ST6jCN) Ingredient Name Strength POLYSORBATE 60 (UNII: CAL22UVI4M) Ingredient Name Strength Sorbit An MONOSTEARATE (UNII: NVZ410H58X) Image: Strength St	Product Inform	nation					
Ingredient/Active Moiety Basis of Strength Strength TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE Ing Inactive Ingredients TRIAMCINOLONE ACETONIDE (UNII: 936)ST6JCN) Ingredient Name Strength CETYL ALCOHOL (UNII: 936)ST6JCN) Ingredient Name Strength Ingredient Name SORBITAN MONOSTEARATE (UNII: NVZ410H58X) SORBITAN MONOSTEARATE (UNII: NVZ410H58X) Ingredient Name Ingredient Name SORBIC ACID (UNII: 20122UVI4M) Ingredient Name Ingredient Name Ingredient Name CETYL ALCOHOL (UNII: 936JST6JCN) Ingredient Name Ingredient Name Ingredient Name POLYSORBATE 60 (UNII: 20122UVI4M) Ingredient Name Ingredient Name Ingredient Name SORBITAN MONOSTEARATE (UNII: NVZ410H58X) Ingredient Name Ingredient Name Ingredient Name GLYCERIN (UNII: 20122FFP9GU) Ingredient Name Ingredient Name Ingredient Name GLYCERIN (UNII: PDC6A3C00X) Ingredient Name Ingredient Name Ingredient Name MATER (UNII: 0599F0K00R) Ingredient Name Ingredient Name Ingredient Name	Route of Administration TOPICAL Active Ingredient/Active Moiety Basis of Strength Strength Ingredient Name Basis of Strength 1 mg TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 1 mg - UNII: F446C597KA) TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 1 mg Inactive Ingredients TRIAMCINOLONE ACETONIDE TRIAMCINOLONE 1 mg CETYL ALCOHOL (UNII: 936JST6JCN) SorbitAn MONOSTEARATE (UNII: NVZ410H58X) Image: Cettyl Esters WAX (UNII: NVZ410H58X) Image: Cettyl Esters WAX (UNII: NVZ410H58X) Image: Cettyl Esters WAX (UNII: D072FFP9GU) Image: Cettyl Esters WAX (UNII: D072FFP9GU) Image: Cettyl Esters WAX (UNII: BCPQ1FFP9GU) Image: Cettyl Esters WAX (UNII: BCPQ2TFFP9GU) Image: Cettyl Estyl Esters WAX (UNII: BCPQ2TFFP9GU)	ltem Code (Sour	ce)	NDC:45802-064				
Ingredient NameBasis of StrengthStrengthTRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDETRIAMCINOLONE1 mg ACETONIDE1 mg in 1 gInactive IngredientsStrengthStrengthStrengthInactive IngredientsStrengthStrengthCETYL ALCOHOL (UNII: 936JST6JCN)Sorbitan MONOSTEARATE (UNII: NVZ4I0H58X)Sorbitan MONOSTEARATE (UNII: NVZ4I0H58X)Sorbitan MONOSTEARATE (UNII: NVZ4I0H58X)Sorbitan MONOSTEARATE (UNII: NVZ4I0H58X)Sorbitan MONOSTEARATE (UNII: S045Wj989B)CETYL ESTERS WAX (UNII: D072FFP9GU)Sorbitan Cetyl (UNII: 20072FFP9GU)StrengthGLYCERIN (UNII: PDC6A3C00X)StrengthStrengthPOPYLENE GLYCOL (UNII: 6DC9Q167V3)StrengthStrength	Ingredient NameBasis of StrengthStrengthTRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDETRIAMCINOLONE1 mg ACETONIDE- UNII:F446C597KA)IngredientsIngredientsInactive IngredientsStrengthCETYL ALCOHOL (UNII: 936JST6JCN)StrengthPOLYSORBATE 60 (UNII: CAL22UVI4M)Sorbitan MONOSTEARATE (UNII: NVZ410H58X)Sorbitan MONOSTEARATE (UNII: NVZ410H58X)Sorbitan MONOSTEARATE (UNII: NVZ410H58X)Sorbita Acid (UNII: 2072FFP9GU)Image: Category (UNII: 2072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)FOPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0KO0R)Image: Category (UNII: 2072FF03M)Isopropyl PALMITATE (UNII: 8CRQ2TH63M)Image: Category (UNII: 2072FF03M)	Route of Administration TOPICAL						
Ingredient NameBasis of StrengthStrengthTRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDETRIAMCINOLONE1 mg ACETONIDE1 mg in 1 gInactive IngredientsStrengthStrengthStrengthInactive IngredientsStrengthStrengthCETYL ALCOHOL (UNII: 936JST6JCN)Sorbitan MONOSTEARATE (UNII: NVZ4I0H58X)Sorbitan MONOSTEARATE (UNII: NVZ4I0H58X)Sorbitan MONOSTEARATE (UNII: NVZ4I0H58X)Sorbitan MONOSTEARATE (UNII: NVZ4I0H58X)Sorbitan MONOSTEARATE (UNII: S045Wj989B)CETYL ESTERS WAX (UNII: D072FFP9GU)Sorbitan Cetyl (UNII: 20072FFP9GU)StrengthGLYCERIN (UNII: PDC6A3C00X)StrengthStrengthPOPYLENE GLYCOL (UNII: 6DC9Q167V3)StrengthStrength	Ingredient NameBasis of StrengthStrengthTRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDETRIAMCINOLONE1 mg ACETONIDE- UNII:F446C597KA)IngredientsIngredientsInactive IngredientsStrengthCETYL ALCOHOL (UNII: 936JST6JCN)StrengthPOLYSORBATE 60 (UNII: CAL22UVI4M)Sorbitan MONOSTEARATE (UNII: NVZ410H58X)Sorbitan MONOSTEARATE (UNII: NVZ410H58X)Sorbitan MONOSTEARATE (UNII: NVZ410H58X)Sorbita Acid (UNII: 2072FFP9GU)Image: Category (UNII: 2072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)FOPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0KO0R)Image: Category (UNII: 2072FF03M)Isopropyl PALMITATE (UNII: 8CRQ2TH63M)Image: Category (UNII: 2072FF03M)							
Ingredient NameBasis of StrengthStrengthTRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDETRIAMCINOLONE1 mg ACETONIDE1 mg in 1 gInactive IngredientsStrengthStrengthStrengthInactive IngredientsStrengthStrengthCETYL ALCOHOL (UNII: 936JST6JCN)StrengthStrengthPOLYSORBATE 60 (UNII: CAL22UVI4M)SorBitan MONOSTEARATE (UNII: NVZ4I0H58X)StrengthSorBitan MONOSTEARATE (UNII: NVZ4I0H58X)StrengthStrengthCETYL ESTERS WAX (UNII: D072FFP9GU)StrengthStrengthGLYCERIN (UNII: PDC6A3C00X)StrengthStrengthPOPYLENE GLYCOL (UNII: 6DC9Q167V3)StrengthStrengthWATER (UNII: 059QF0KOOR)StrengthStrength	Ingredient NameBasis of StrengthStrengthTRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDETRIAMCINOLONE1 mg ACETONIDE1 mg in 1 gInactive IngredientsIngredient NameStrengthCETYL ALCOHOL (UNII: 936JST6JCN)StrengthStrengthPOLYSORBATE 60 (UNII: CAL22UVI4M)Sorbitan MONOSTEARATE (UNII: NVZ4I0H58X)SSorbitan MONOSTEARATE (UNII: NVZ4I0H58X)SSSorbitan MONOSTEARATE (UNII: NO12FFP9GU)SSGLYCERIN (UNII: PDC6A3C00X)SSPROPYLENE GLYCOL (UNII: 6DC9Q167V3)S	Active Ingredie	ent/Active	Moiety				
TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE ACETONIDE ACETONIDE ACETONIDE ACETONIDE (UNII: F446C597KA) 1 mg in 1 g Inactive Ingredients Ingredient Name Strength CETYL ALCOHOL (UNII: 936JST6JCN) Strength POLYSORBATE 60 (UNII: CAL22UVI4M)	TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 1 mg - UNII:F446C597KA) Ingredients 1 mg Inactive Ingredients Strength CETYL ALCOHOL (UNII: 936JST6JCN) Strength POLYSORBATE 60 (UNII: CAL22UVI4M) SorBitAn MONOSTEARATE (UNII: NVZ4I0H58X) SorBitC ACID (UNII: x045WJ989B) SorBitC ACID (UNII: x045WJ989B) CETYL ESTERS WAX (UNII: D072FFP9GU) Import GLYCERIN (UNII: PDC6A3C00X) Import PROPYLENE GLYCOL (UNII: 6DC9Q167V3) Import WATER (UNII: 059QF0KO0R) Import Isopropyl PALMITATE (UNII: 8CRQ2TH63M) Import			-		Basis of S	trength Str	engt
Inactive IngredientsStrengthIngredient NameStrengthCETYL ALCOHOL (UNII: 936JST6JCN)POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ 4I0H58X)SORBIC ACID (UNII: X045WJ989B)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0K00R)	Inactive IngredientsStrengthIngredient NameStrengthCETYL ALCOHOL (UNII: 936JST6JCN)POLYSORBATE 60 (UNII: CAL22UVI4M)POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)SORBIC ACID (UNII: X045WJ989B)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C0OX)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0KO0R)ISOPROPYL PALMITATE (UNII: 8CRQ2TH63M)	-					-	-
Ingredient NameStrengthCETYL ALCOHOL (UNII: 936JST6JCN)POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)SORBIC ACID (UNII: X045W989B)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0K00R)	Ingredient NameStrengthCETYL ALCOHOL (UNII: 936JST6JCN)POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)SORBIC ACID (UNII: X045WJ989B)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0K00R)ISOPROPYL PALMITATE (UNII: 8CRQ2TH63M)	- UNII:F446C597KA) ACETONIDE					in 1	1 g
Ingredient NameStrengthCETYL ALCOHOL (UNII: 936JST6JCN)POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ 410H58X)SORBIC ACID (UNII: X045WJ989B)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0K00R)	Ingredient NameStrengthCETYL ALCOHOL (UNII: 936JST6JCN)POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)SORBIC ACID (UNII: X045WJ989B)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0K00R)ISOPROPYL PALMITATE (UNII: 8CRQ2TH63M)	Inactive Ingree	dients					
CETYL ALCOHOL (UNII: 936JST6JCN)POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)SORBIC ACID (UNII: X045WJ989B)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0K00R)	CETYL ALCOHOL (UNII: 936JST6JCN)POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)SORBIC ACID (UNII: X045WJ989B)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0K00R)ISOPROPYL PALMITATE (UNII: 8CRQ2TH63M)	inactive ingret		Ingredient Name			Strengt	th
POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)CETYL ESTERS WAX (UNII: D072FFP9GU)CETYL ESTERS WAX (UNII: D072FFP9GU)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0K00R)CETYL ESTERS WAX (UNII: D072FFP9GU)	POLYSORBATE 60 (UNII: CAL22UVI4M)SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)Image: Colored colo	CETYL ALCOHOL (ા	JNII: 936IST6IC	-			j-	
SORBITAN MONOSTEARATE (UNII: NVZ 410H58X)SORBIC ACID (UNII: X045Wj989B)CETYL ESTERS WAX (UNII: D072FFP9GU)GLYCERIN (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)WATER (UNII: 059QF0K00R)	SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)Image: Sorbic Acid (UNII: X045Wj989B)SORBIC ACID (UNII: X045Wj989B)Image: Sorbic Acid (UNII: D072FFP9GU)CETYL ESTERS WAX (UNII: D072FFP9GU)Image: Sorbic Acid (UNII: PDC6A3C00X)GLYCERIN (UNII: PDC6A3C00X)Image: Sorbic Acid (UNII: 6DC9Q167V3)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)Image: Sorbic Acid (UNII: 059QF0K00R)WATER (UNII: 059QF0K00R)Image: Sorbic Acid (UNII: 8CRQ2TH63M)							
SORBIC ACID (UNII: X045W989B)Image: Ceryl esters wax (UNII: D072FFP9GU)CETYL ESTERS WAX (UNII: D072FFP9GU)Image: Ceryl esters wax (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)Image: Ceryl esters water (UNII: 059QF0K00R)	SORBIC ACID (UNII: X045WJ989B)Image: CeryL esters wax (UNII: D072FFP9GU)CETYL ESTERS WAX (UNII: D072FFP9GU)Image: CeryL esters wax (UNII: PDC6A3C00X)PROPYLENE GLYCOL (UNII: 6DC9Q167V3)Image: CeryL esters wax esters (UNII: 059QF0K00R)WATER (UNII: 059QF0K00R)Image: CeryL esters wax esters (UNII: 8CRQ2TH63M)							
GLYCERIN (UNII: PDC6A3C0OX) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) WATER (UNII: 059QF0KO0R)	GLYCERIN (UNII: PDC6A3C0OX) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) WATER (UNII: 059QF0KO0R) ISOPROPYL PALMITATE (UNII: 8CRQ2TH63M)	SOURCE AND MONTAN						
PROPYLENE GLYCOL (UNII: 6DC9Q167V3) WATER (UNII: 059QF0KO0R)	PROPYLENE GLYCOL (UNII: 6DC9Q167V3) WATER (UNII: 059QF0K00R) ISOPROPYL PALMITATE (UNII: 8CRQ2TH63M)			FP9GU)				
WATER (UNII: 059QF0KO0R)	WATER (UNII: 059QF0KO0R) ISOPROPYL PALMITATE (UNII: 8CRQ2TH63M)	SORBIC ACID (UNII:						
	ISOPROPYL PALMITATE (UNII: 8CRQ2TH63M)	SORBIC ACID (UNII: CETYL ESTERS WA						
		SORBIC ACID (UNII: CETYL ESTERS WA GLYCERIN (UNII: PDO	C6A3C0OX)	Q167V3)				
		SORBIC ACID (UNII: CETYL ESTERS WA GLYCERIN (UNII: PDO PROPYLENE GLYCC	C6A3C0OX) DL (UNII: 6DC9	Q167V3)				

Packaging						
# Item Code	Package Description	Marketing Start Date	Marketing End Date			
1 NDC:45802-064- 36	1 in 1 CARTON					
1	80 g in 1 TUBE; Type 0: Not a Combination Product					
Marketing	Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
ANDA	ANDA086413	09/28/2006				
Marketing	Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
unapproved drug other		09/28/2006				

Labeler - NuCare Pharmaceuticals,Inc. (010632300)

Establishment				
Name	Address	ID/FEI	Business Operations	
NuCare Pharmaceuticals, Inc.		010632300	manufacture(70859-054)	

Revised: 7/2023

NuCare Pharmaceuticals, Inc.